Alastair O’Brien

3.6k citations

64 papers · 1.9k indexed · 3 hit papers · h-index 21

Co-authors: Derek W. Gilroy Louise China James N. Fullerton Roger Williams Mervyn Singer Suvi Härmälä Ewan Forrest Pere Ginès
Topics: Liver Disease Diagnosis and Treatment (43 papers)Liver Disease and Transplantation (37 papers)Drug-Induced Hepatotoxicity and Protection (14 papers)
Cited by: Hepatology Epidemiology Pharmacology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United Kingdom United States Spain

In The Last Decade

Alastair O’Brien

59 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines on the management of ascites in cirrhosis

2020 240 citations Guruprasad P. Aithal, Naaventhan Palaniyappan et al. Gut profile →
Albumin in decompensated cirrhosis: new concepts and perspectives

2020 211 citations Mauro Bernardi, Paolo Angeli et al. Gut profile →
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

2021 194 citations Louise China, Nick Freemantle et al. profile →

Peers

Countries citing papers authored by Alastair O’Brien

Since Specialization

Citations

This map shows the geographic impact of Alastair O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alastair O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alastair O’Brien more than expected).

Fields of papers citing papers by Alastair O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alastair O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alastair O’Brien. The network helps show where Alastair O’Brien may publish in the future.

Co-authorship network of co-authors of Alastair O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Alastair O’Brien. A scholar is included among the top collaborators of Alastair O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alastair O’Brien. Alastair O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE 2025 ·Annals of Hepatology ·Nikolaj Torp,Louise China,Mads Israelsen,Ewan Forrest,Nick Freemantle,Jonel Trebicka,Aleksander Krag,Alastair O’Brien	1
2	Antimicrobial prophylaxis in decompensated cirrhosis: friend or foe? 2023 ·Hepatology Communications ·Dominic Crocombe,Alastair O’Brien	6
3	Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial 2023 ·EClinicalMedicine ·Louise China,(unknown),Dominic Crocombe,Ewan Forrest,Yiannis Kallis,Stephen Ryder,Gavin Wright,Nick Freemantle,Alastair O’Brien	8
4	Cirrhosis in over 16s: assessment and management—updated summary of NICE guidance 2023 ·BMJ ·Chris Carmona,Lindsay Claxton,Alastair O’Brien,Vanessa Hebditch	4
5	Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV‐negative controls: A cross‐sectional study nested within the POPPY cohort 2023 ·HIV Medicine ·Alejandro Arenas‐Pinto,(unknown),Ana Milinkovic,Ian Williams,Jaime H. Vera,Frank A. Post,Jane Anderson,Michelle Beynon,Alastair O’Brien,(unknown),Richard Gilson,Sarah Pett,Alan Winston,Caroline Sabin	4
6	Long-term albumin treatment in patients with cirrhosis and ascites 2022 ·Journal of Hepatology ·Paolo Caraceni,Alastair O’Brien,Pere Ginès	38
7	Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: data from the ATTIRE trial 2022 ·EClinicalMedicine ·(unknown),Louise China,Ewan Forrest,Yiannis Kallis,Stephen Ryder,Gavin Wright,Nick Freemantle,Alastair O’Brien	6
8	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway 2021 ·JHEP Reports ·Alexander A. Maini,Natalia Bécares,Louise China,(unknown),Amit Patel,Roel P. H. De Maeyer,Nekisa Zakeri,(unknown),Lucy Ly,Derek W. Gilroy,Alastair O’Brien	7
9	Guidelines on the management of ascites in cirrhosisbreakdown → 2020 ·Gut ·Guruprasad P. Aithal,Naaventhan Palaniyappan,Louise China,Suvi Härmälä,Lucia Macken,Jennifer Ryan,Emilie Wilkes,Kevin Moore,Joanna Leithead,Peter Hayes,Alastair O’Brien,Sumita Verma	240
10	Albumin in decompensated cirrhosis: new concepts and perspectivesbreakdown → 2020 ·Gut ·Mauro Bernardi,Paolo Angeli,Joan Clària,Richard Moreau,Pere Ginès,Rajiv Jalan,Paolo Caraceni,Javier Fernández,Alexander L. Gerbes,Alastair O’Brien,Jonel Trebicka,Thierry Thévenot,Vicente Arroyo	211
11	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19 2020 ·Pharmacology & Therapeutics ·Derek W. Gilroy,Roel P. H. De Maeyer,Mark A. Tepper,Alastair O’Brien,Mohib Uddin,Judy Chen,Daniel R. Goldstein,Arne N. Akbar	8
12	Effectiveness of intravenous albumin therapy to prevent spontaneous bacterial peritonitis, renal dysfunction and death in adults with cirrhosis: a protocol for a systematic review 2019 ·BMJ Open ·Suvi Härmälä,Constantinos A. Parisinos,Jennifer Ryan,Alastair O’Brien	1
13	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial 2019 ·BMJ Open ·(unknown),Vishal Patel,Simon Goldenberg,Alberto Sánchez‐Fueyo,Louise China,Alastair O’Brien,Clare Flach,Abdel Douiri,Debbie L. Shawcross	21
14	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial 2017 ·Clinical Gastroenterology and Hepatology ·Louise China,Simon S. Skene,Zainib Shabir,Alexander A. Maini,Yvonne Sylvestre,Kate Bennett,(unknown),James O’Beirne,Ewan Forrest,(unknown),Stephen Ryder,Gavin Wright,Derek W. Gilroy,Alastair O’Brien	19
15	Antimicrobial resistance in liver disease: better diagnostics are needed 2017 ·The Lancet. Gastroenterology & hepatology ·Laura Shallcross,Alastair O’Brien	6
16	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial 2016 ·BMJ Open ·Louise China,Nicola Muirhead,Simon S. Skene,Zainib Shabir,Roel P. H. De Maeyer,Alexander A. Maini,Derek W. Gilroy,Alastair O’Brien	6
17	PTH-102 Stat2 is a key inflammatory molecule in human non-alcoholic fatty liver disease and murine liver injury 2015 ·William Alazawi,(unknown),Gemma Petts,(unknown),Roger Feakins,Alastair O’Brien,Robert Goldin,Graham R. Foster	2
18	Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5 2015 ·Annals of Surgery ·Rajiv Lahiri,Yannick Derwa,(unknown),Edward Giles,Hew D.T. Torrance,Helen C. Owen,Michael J. O’Dwyer,Alastair O’Brien,Andrew J. Stagg,Satyajit Bhattacharya,Graham R. Foster,William Alazawi	41
19	Lipid mediators in immune dysfunction after severe inflammation 2013 ·Trends in Immunology ·James N. Fullerton,Alastair O’Brien,Derek W. Gilroy	74
20	The pore‐forming subunit of the K_ATP channel is an important molecular target for LPS‐induced vascular hyporeactivity in vitro 2005 ·British Journal of Pharmacology ·Alastair O’Brien,(unknown),(unknown),Mervyn Singer,Lucie H. Clapp	30

About Alastair O’Brien

Alastair O’Brien is a scholar working on Hepatology, Pharmacology and Epidemiology, having authored 64 papers that have together received 1.9k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (43 papers), Liver Disease and Transplantation (37 papers) and Drug-Induced Hepatotoxicity and Protection (14 papers). The work is most often cited by research in Hepatology (1.1k citations), Epidemiology (1.1k citations) and Pharmacology (238 citations). Alastair O’Brien has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Derek W. Gilroy, Louise China, James N. Fullerton, Roger Williams, Mervyn Singer, Suvi Härmälä, Ewan Forrest, Pere Ginès, Paolo Caraceni and Nick Freemantle. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact